Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Genito-urinary Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1408)
News
Trials
Search handles
@ADesaiMD
@A_CT_SimMDJD
@AaronGoodman33
@AdamSharpMedOnc
@AdityaBagrodia
@AkashPatnaik7
@AldoLADETTINO
@AmandaNizamMD
@AmarUKishan
@AnaVManana
@AndreaNecchi
@AndreasC466
@ArndtVogel
@AshwinShindeMD
@AtishChoudhury
@AzadOncology
@BenWestphalen
@BenjaminBesseMD
@BenjaminPradere
@BijoyTelivala
@BourlonMaite
@BradMcG04
@BraunMDPhD
@BrunoBastosMD
@CJTsaiMDPhD
@CParkMD
@CathyHandy
@ChadTangMD
@ChapinMD
@CharlesJiangMD
@CharuAggarwalMD
@ChrisFloresRT
@ChristianRolfo
@ChungHanLee3
@ClarkHenegan
@Cold_Steel_1970
@CyclingDoctor
@Daniel_Urologia
@DavidLMayhew
@DavidRSpigel
@DrAndrewLoblaw
@DrBonillaOnc
@DrChoueiri
@DrCraigGedye
@DrDanielHeng
@DrDarrenPoon
@DrFelixGuerrero
@DrJJZhang
@DrJuneJD
@DrLesterColl
@DrRanaMcKay
@DrScottTagawa
@DrSpratticus
@DrTylerStewart
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_RShatsky
@Dr_R_Kurzrock
@Dr_RaviMadan
@DrewMoghanaki
@ERPlimackMD
@ESchattner
@EfstathiouEleni
@EladSharonMD
@EllisLab_
@EnriqueGallar12
@EvanHallMD
@FAndreMD
@FDonskov
@FSchlurmann
@FaltasLab
@FawziAbuRous
@FernandoOnco
@FuenteApolo
@FunchainMD
@GGiannarini
@GIcancerDoc
@GMIannantuonoMD
@GertMeerleer
@GitaSuneja
@GiulioFrancoli1
@GlopesMd
@GustavoVillold4
@HHammersMD
@HassanSheikh_MD
@HenningWillers
@HimanshuNagarMD
@IBCradiation
@Icro_Meattini
@IshwariaMD
@JTrentMDPhD
@JadChahoud
@JasonBrownMDPhD
@JoshLangMD
@JoshMeeks
@JuddMoul
@KMaxwellLab
@KMittalmd
@KamravaMD
@KeithKow
@KerwinXRT
@KidneyCancerDoc
@KonradStawiski
@KrisWentzelMD
@Latinamd
@LauraBukavinaMD
@LeoNissolaMD
@LindaMileshkin
@LoebStacy
@LondonProstate1
@LuisCB_MedPharm
@LuisSalgadoS
@LujanPomponio
@MLPOncoData
@MPishvaian
@MRHarrisonMD
@Martin_AngelMD
@Mat_Guc
@MattGalsky
@MichalisLiontos
@Monthy_A
@MosheOrnsteinMD
@NDeVitoMD
@NagiSaghir
@NazliDizman
@NeimanVictoria
@NicholasZaorsky
@NicoleKuderer
@NimaSharifiMD
@NiuSanford
@NormandBlais
@OmidHamidMD
@OncHahn
@OncoBellmunt
@OncoLucus
@PBarataMD
@PBlanchardMD
@PGrivasMDPhD
@PLMcCarthyMD
@Panos_Vlach
@ParamMariappan
@ParikhSimul
@PatrickHwuMD
@PaulSargos
@PauloBergerot
@PavlosMsaouel
@PrimoLaraMD
@ProfPadhani
@ProfSyedHussain
@Prof_IanD
@Prof_Nick_James
@RPachynski
@RachelRiechelm2
@RandySweisMD
@ReneeSaliby
@Rfonsi1
@RicBertolo
@RohanGarjeMD
@SJFrankMD
@SWilliams_MD
@SalemGIOncDoc
@ShannonWestin
@ShepardDale
@ShingoHatakeya1
@ShuchiGulati
@SirohiBhawna
@SoaresAndrey
@StoverLab
@Sushilberiwal
@SuyogCancer
@SyedAAhmad5
@SyedMAhmedMDPhD
@TapiaJC1
@TheWonkologist
@TiansterZhang
@TomFlaigMD
@Tony_Calles
@TylerSbrt
@UroDocAsh
@UrologieParis
@VamsiVelcheti
@VedangMurthy
@ViktorGruenwald
@VivekSubbiah
@VoglNY
@WalterStadler5
@WesKassouf
@ZilliThomas
@_ShankarSiva
@a_nourallah
@aadel_chaudhuri
@abhenilmittal
@abhisingh82
@achoud72
@aftimosp
@akeithstewart
@alantanmd
@aleberlin2
@alirezaghoreifi
@alison_tree
@alongi_filippo
@alshamsi2000
@amerseburger
@anandoncologist
@anita_turk
@apolo_andrea
@arihakimi
@arkhaki
@barrosonco
@bergsa83
@bilenma
@binayshah
@bpiperdi
@brian_rini
@calliecoombsmd
@cancerassassin1
@cczielinski
@cdanicas
@chadinabhan
@charlesryanmd
@chulkimMD
@crisuarez08
@d_shapiro1
@davidhenrymd
@daviesbj
@dawood_findakly
@declangmurphy
@dhjutsw1
@dipenjparekh
@docjavip
@docpriyamvada
@dralvaropinto
@drcbsteer
@drdeniztural
@drenriquegrande
@drgandara
@drjamesgood
@drlw2309
@drmnstein
@drsfrees
@duemed
@elizabeth_budde
@fedelosco
@fmassari79
@freddyeescorcia
@fsabino_onco
@g_develasco
@gbanna74
@gerryhanna
@giga_fra
@gulleyj1
@heinrich_kat
@herbloong
@itinay
@jamecancerdoc
@jasonlukemd
@jeffyoriomd
@jesusanampa
@jgong15
@jimhumd
@joanfundi
@jryckman3
@jsoriamd
@kakeegs3
@kdjhaveri
@kmody29
@koshkin85
@majorajay
@malvarezmaestro
@montypal
@motajmsc
@mtmdphd
@mtsiatas
@n8pennell
@naborala
@nataliagandur
@navstruck
@neerajaiims
@nirvanaformiga
@oalhalabimd
@othmanmo
@outliersbio
@pashtoonkasi
@pcvblack
@pekijammer
@quimmateo
@radiolobt
@radioncoluis
@ravi_b_parikh
@rcarvalhoonco
@romeerizwan
@saadvikdr
@sandraturner49
@scserendipity1
@sejadiMD
@sgilbert1973
@shilpaonc
@sonpavde
@subatomicdoc
@tmprowell
@toddscarbrough
@tomboike
@tompowles1
@ugm6pfm
@uroegg
@vinay_onc
@weldeiry
@weoncologists
@yekeduz_emre
@young_whang
@zapatalaguadomd
Search handles
@ADesaiMD
@A_CT_SimMDJD
@AaronGoodman33
@AdamSharpMedOnc
@AdityaBagrodia
@AkashPatnaik7
@AldoLADETTINO
@AmandaNizamMD
@AmarUKishan
@AnaVManana
@AndreaNecchi
@AndreasC466
@ArndtVogel
@AshwinShindeMD
@AtishChoudhury
@AzadOncology
@BenWestphalen
@BenjaminBesseMD
@BenjaminPradere
@BijoyTelivala
@BourlonMaite
@BradMcG04
@BraunMDPhD
@BrunoBastosMD
@CJTsaiMDPhD
@CParkMD
@CathyHandy
@ChadTangMD
@ChapinMD
@CharlesJiangMD
@CharuAggarwalMD
@ChrisFloresRT
@ChristianRolfo
@ChungHanLee3
@ClarkHenegan
@Cold_Steel_1970
@CyclingDoctor
@Daniel_Urologia
@DavidLMayhew
@DavidRSpigel
@DrAndrewLoblaw
@DrBonillaOnc
@DrChoueiri
@DrCraigGedye
@DrDanielHeng
@DrDarrenPoon
@DrFelixGuerrero
@DrJJZhang
@DrJuneJD
@DrLesterColl
@DrRanaMcKay
@DrScottTagawa
@DrSpratticus
@DrTylerStewart
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_RShatsky
@Dr_R_Kurzrock
@Dr_RaviMadan
@DrewMoghanaki
@ERPlimackMD
@ESchattner
@EfstathiouEleni
@EladSharonMD
@EllisLab_
@EnriqueGallar12
@EvanHallMD
@FAndreMD
@FDonskov
@FSchlurmann
@FaltasLab
@FawziAbuRous
@FernandoOnco
@FuenteApolo
@FunchainMD
@GGiannarini
@GIcancerDoc
@GMIannantuonoMD
@GertMeerleer
@GitaSuneja
@GiulioFrancoli1
@GlopesMd
@GustavoVillold4
@HHammersMD
@HassanSheikh_MD
@HenningWillers
@HimanshuNagarMD
@IBCradiation
@Icro_Meattini
@IshwariaMD
@JTrentMDPhD
@JadChahoud
@JasonBrownMDPhD
@JoshLangMD
@JoshMeeks
@JuddMoul
@KMaxwellLab
@KMittalmd
@KamravaMD
@KeithKow
@KerwinXRT
@KidneyCancerDoc
@KonradStawiski
@KrisWentzelMD
@Latinamd
@LauraBukavinaMD
@LeoNissolaMD
@LindaMileshkin
@LoebStacy
@LondonProstate1
@LuisCB_MedPharm
@LuisSalgadoS
@LujanPomponio
@MLPOncoData
@MPishvaian
@MRHarrisonMD
@Martin_AngelMD
@Mat_Guc
@MattGalsky
@MichalisLiontos
@Monthy_A
@MosheOrnsteinMD
@NDeVitoMD
@NagiSaghir
@NazliDizman
@NeimanVictoria
@NicholasZaorsky
@NicoleKuderer
@NimaSharifiMD
@NiuSanford
@NormandBlais
@OmidHamidMD
@OncHahn
@OncoBellmunt
@OncoLucus
@PBarataMD
@PBlanchardMD
@PGrivasMDPhD
@PLMcCarthyMD
@Panos_Vlach
@ParamMariappan
@ParikhSimul
@PatrickHwuMD
@PaulSargos
@PauloBergerot
@PavlosMsaouel
@PrimoLaraMD
@ProfPadhani
@ProfSyedHussain
@Prof_IanD
@Prof_Nick_James
@RPachynski
@RachelRiechelm2
@RandySweisMD
@ReneeSaliby
@Rfonsi1
@RicBertolo
@RohanGarjeMD
@SJFrankMD
@SWilliams_MD
@SalemGIOncDoc
@ShannonWestin
@ShepardDale
@ShingoHatakeya1
@ShuchiGulati
@SirohiBhawna
@SoaresAndrey
@StoverLab
@Sushilberiwal
@SuyogCancer
@SyedAAhmad5
@SyedMAhmedMDPhD
@TapiaJC1
@TheWonkologist
@TiansterZhang
@TomFlaigMD
@Tony_Calles
@TylerSbrt
@UroDocAsh
@UrologieParis
@VamsiVelcheti
@VedangMurthy
@ViktorGruenwald
@VivekSubbiah
@VoglNY
@WalterStadler5
@WesKassouf
@ZilliThomas
@_ShankarSiva
@a_nourallah
@aadel_chaudhuri
@abhenilmittal
@abhisingh82
@achoud72
@aftimosp
@akeithstewart
@alantanmd
@aleberlin2
@alirezaghoreifi
@alison_tree
@alongi_filippo
@alshamsi2000
@amerseburger
@anandoncologist
@anita_turk
@apolo_andrea
@arihakimi
@arkhaki
@barrosonco
@bergsa83
@bilenma
@binayshah
@bpiperdi
@brian_rini
@calliecoombsmd
@cancerassassin1
@cczielinski
@cdanicas
@chadinabhan
@charlesryanmd
@chulkimMD
@crisuarez08
@d_shapiro1
@davidhenrymd
@daviesbj
@dawood_findakly
@declangmurphy
@dhjutsw1
@dipenjparekh
@docjavip
@docpriyamvada
@dralvaropinto
@drcbsteer
@drdeniztural
@drenriquegrande
@drgandara
@drjamesgood
@drlw2309
@drmnstein
@drsfrees
@duemed
@elizabeth_budde
@fedelosco
@fmassari79
@freddyeescorcia
@fsabino_onco
@g_develasco
@gbanna74
@gerryhanna
@giga_fra
@gulleyj1
@heinrich_kat
@herbloong
@itinay
@jamecancerdoc
@jasonlukemd
@jeffyoriomd
@jesusanampa
@jgong15
@jimhumd
@joanfundi
@jryckman3
@jsoriamd
@kakeegs3
@kdjhaveri
@kmody29
@koshkin85
@majorajay
@malvarezmaestro
@montypal
@motajmsc
@mtmdphd
@mtsiatas
@n8pennell
@naborala
@nataliagandur
@navstruck
@neerajaiims
@nirvanaformiga
@oalhalabimd
@othmanmo
@outliersbio
@pashtoonkasi
@pcvblack
@pekijammer
@quimmateo
@radiolobt
@radioncoluis
@ravi_b_parikh
@rcarvalhoonco
@romeerizwan
@saadvikdr
@sandraturner49
@scserendipity1
@sejadiMD
@sgilbert1973
@shilpaonc
@sonpavde
@subatomicdoc
@tmprowell
@toddscarbrough
@tomboike
@tompowles1
@ugm6pfm
@uroegg
@vinay_onc
@weldeiry
@weoncologists
@yekeduz_emre
@young_whang
@zapatalaguadomd
Filter by
Latest
9ms
Tell me about ATM alterations for the treatment of bladder cancer please. (@ClemensLaseur)
9 months ago
ATM (ATM serine/threonine kinase)
9ms
Excited to see the latest @charlesrudin lab paper published in @ScienceTM: "Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers". #lungcancer #prostatecancer #SCLC #lineageplasticity https://t.co/sKHYNaave7 (@AlvaroQuintanal)
9 months ago
SOX2 • XPO1 (Exportin 1)
9ms
Unlocking #ProstateCancer treatment: The pathway of CAR T targeting prostate stem cell antigen. @TDorffOnc @cityofhope joins @CaPsurvivorship @DanaFarber to discuss promising options in managing advanced castration-resistant prostate cancer > https://t.co/fyZMrf16Uz (@urotoday)
9 months ago
Metastases
|
PSCA (Prostate Stem Cell Antigen 2)
9ms
We reported in 2021 p21 & Rb truncating mutations in kidney chromophobe renal cell carcinomas with suspected implications for therapy & pathogenesis. I’m fascinated by p21 & Rb truncating mutations in bladder tumors as well. More research is needed. https://t.co/RrwEr4G0Tv (@weldeiry)
9 months ago
CDKN1A (Cyclin-dependent kinase inhibitor 1A)
9ms
Thrilled to share the stage with @LauraBukavinaMD at #BCANTT23! I'll be delving into 'PPARG the Rogue Conductor's Broken Harmony: How MAPK Pathway Alterations Drive Bladder Cancer Progression,' a new paradigm in bladder cancer. Looking forward to an exciting exchange of ideas! (@RaieBekele)
9 months ago
PPARG (Peroxisome Proliferator Activated Receptor Gamma)
9ms
From science to clinical utility: @Cxbladder Detect - #BladderCancer detection for patients who present with hematuria. Tamer Aboushwareb, MD, PhD @PacificEdgeLtd, Neal Shore, MD, FACS @AtlanticUrology & @JoshMeeks @NM_Urology join to discuss on UroToday > https://t.co/ntpVmbLok6 (@urotoday)
9 months ago
Clinical
|
Cxbladder
9ms
Beyond BRCA-1 and 2: The impact of the #TALAPRO2 study on #ProstateCancer care. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship @DanaFarber to discuss precision medicine's transformative impact on prostate cancer treatment. #WatchNow > https://t.co/1wCyan0v6L (@urotoday)
9 months ago
BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
9ms
A recent study published in JNCI Cancer Spectrum demonstrates the real-world utility of @Veracyte's #Decipher Prostate Genomic Classifier in #ProstateCancer treatment. #ReadNow details on UroToday > https://t.co/NOVWZFh6wC @JNCI_Now @DrSpratticus @Davicioni (@urotoday)
9 months ago
Clinical • Real-world evidence • Real-world
|
Decipher Prostate Cancer Test
9ms
1. Lessons from Melanoma: Building on PD1 backbone w/ CTLA/LAG3 (FS Hodi, @wolchokj, @MPostow) 2. What’s new in IrAE mgmt? @DrJNaidoo @CardioOncology @kreynoldsMD 3. RCC Germline Genetics: Past, Present, Future (Linehan,@KidneyCancerDoc @pearldaily) 4. @kidneycan FallAdvocacy (@MikeSerzanMD)
9 months ago
IO biomarker
|
PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3)
9ms
PSMA-targeted radioligand therapy and #LiquidBiopsy characterizing #PSMA expression in men with metastatic castration-resistant #ProstateCancer. @AarmstrongDuke @DukeCancer joins @AndreaMiyahira @PCFnews to discuss the #PROPHECY trial on UroToday > https://t.co/tTiFnUVJOv (@urotoday)
9 months ago
Liquid biopsy • Metastases
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 expression
9ms
Results from the phase 1b/2 #FIDES02 study: Derazantinib for metastatic #BladderCancer with activating FGFR1/2/3 genetic aberrations. @AndreaNecchi @SanRaffaeleMI joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/7XkvtuwvBN (@urotoday)
9 months ago
Metastases
|
FGFR1 (Fibroblast growth factor receptor 1)
|
derazantinib (ARQ 087)
9ms
.@neerajaiims, of @huntsmancancer, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC. #pcsm https://t.co/xbusmBgW8j (@OncLive)
9 months ago
HRD (Homologous Recombination Deficiency)
|
Talzenna (talazoparib) • Xtandi (enzalutamide capsule)
9ms
Could the design of CONTACT-03 have been improved with a PD-1 rather than a PD-L1? @PBarataMD shares his thoughts on this and other aspects of CONTACT-03 in our recent roundtable...https://t.co/8787qeeN80 #kidneycancer (@GUOncologyNow)
9 months ago
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
9ms
Radio day! Join me today 6-8pE on @SIRIUSXM 110 @NYUDocs for a great program-@heatherhcheng & @CureBRCA on #BRCA in men, the @PCFnews prostate segment on surgery & radiation w Dr Shore, disparities in #prostatecancer w @hypertensionmd &drug induced erectile problems w @MariaUloko (@LoebStacy)
9 months ago
Surgery
|
BRCA (Breast cancer early onset)
9ms
For patients with HRR gene–mutated mCRPC, additional data supporting the use of the combination of the PARP inhibitor talazoparib with enzalutamide is a welcome signal in the field. @neerajaiims @huntsmancancer #pcsm https://t.co/QMXZaAaaoU (@OncLive)
9 months ago
Clinical
|
HRD (Homologous Recombination Deficiency)
|
Talzenna (talazoparib) • Xtandi (enzalutamide capsule)
9ms
GU events are definitely a highlight of the @NRGonc meeting!! #NRG10 #NRG2023 Also huge congrats @tomboike for being named a 2023 @ASTRO_org Fellow (FASTRO)!! So exciting!! @MROQC1 represent 🙌👌 #pcsm #gusm #radonc (@jaguaranna27)
9 months ago
NRG2 (Neuregulin 2)
9ms
Discover the complexities of PSMA heterogeneity and regulation in metastatic #ProstateCancer with AR-positive and AR-negative phenotypes in this insightful discussion with @mishabeltran @DanaFarber and @AndreaMiyahira @PCFnews. #WatchNow on UroToday > https://t.co/pSgn6fDbJ3 (@urotoday)
9 months ago
Metastases
|
AR (Androgen receptor)
|
AR positive • AR negative
9ms
Insightful discussion with @y_loriot on the randomized #THOR study data that he presented at #ASCO23, confirming efficacy of Erdafitinib in FGFR3-altered platinum-refractory patients with #BladderCancer @ASCO @BladderCancerUS @IBCG_BladderCA @onclive @Uromigos (@koshkin85)
9 months ago
Clinical
|
FGFR3 (Fibroblast growth factor receptor 3)
|
Balversa (erdafitinib)
9ms
It’s been wonderful catching up with my incredibly talented & hardworking mentors in #GU #GUSM #ProstateCancer at @NRGonc #NRG10 #NRG2023 including legends: 1️⃣ Dr. Daniel Spratt @DrSpratticus (@RadOncUH Chair via @UMichRadOnc, @MSKCancerCenter, & @VUMChealth:… https://t.co/5NetDokMzx (@jaguaranna27)
9 months ago
NRG2 (Neuregulin 2)
9ms
Primary analysis of #STARTAR: a phase 2 salvage trial for high-risk #ProstateCancer with biochemical recurrence. @TiansterZhang @utsw joins @CaPsurvivorship @DanaFarber to discuss treatment intensification in this conversation on UroToday > https://t.co/5NNRmuD48f (@urotoday)
9 months ago
9ms
#DDHO2023 is kicking off now with this #genitourinarycancer session with @bilenma @jackiebrown_MD @virajmaster @BasselNazha and other experts! @WinshipAtEmory (@BioAscend)
9 months ago
9ms
💫🌟Hospital Anxiety and Depression Scale Score Trends Among Testicular Cancer Survivors: a Longitudinal Study - Khalid Alkhatib🌟💫 Recommended!!📚📖👇 @urotoday @OncoAlert @OncoReporte #OncoAlertAF @InstitutoRoffo @SauUrologia @CAU_URO @lacort @SolcaGuayaquil @shilpaonc… https://t.co/XmAo5mIYoO (@nataliagandur)
9 months ago
Clinical • Observational data
9ms
Just in @trendscancer @CellPressNews 👉Recent advances in advanced #prostatecancer Rx: Lu-177, PARPi combos in mCRPC, doublets/triplets in mCSPC, and evolving targets👇 Weblink: https://t.co/L0cokxjZFd @ggebraelmd @GliceidaGalarza @umangtalking @OncoAlert @PCF_Science @urotoday (@neerajaiims)
9 months ago
Metastases
9ms
Effective Treatment Options and Sequencing for Patients With Castration-Resistant #ProstateCancer Listen to Ep 2 of the @Medscape Prostate Cancer podcast series with host @sandysrimd and guest @shilpaonc. https://t.co/MLkFf7wjOc (@caseyannhickey)
9 months ago
Clinical
9ms
Agarwal Discusses FDA Approval of Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC @neerajaiims @huntsmancancer @ASCO #ASCO23 #pcsm https://t.co/IIAaAi2fho (@OncLive)
9 months ago
FDA event
|
HRD (Homologous Recombination Deficiency)
|
Talzenna (talazoparib) • Xtandi (enzalutamide capsule)
9ms
Beautiful paper from @ggebraelmd, mentored by @neerajaiims @huntsmancancer, on the heels of his fantastic presentation at #KCRS23! Whether #kidneycancer or #prostatecancer, his command of the science and literature are amazing!!! @NeliMUlrich (@montypal)
9 months ago
9ms
A very insightful commentary by Francesca Jackson-Spence, Matthew Young, @ChrisSweens1, and @tompowles1, who have highlighted the latest data on the treatment of #GenitourinaryCancer! Read the #OpenAccess article in @JournalCancer ⬇️ https://t.co/ze3niNLU7J (@OncoViews)
9 months ago
9ms
Healio spoke with @LoebStacy regarding data showing that Black individuals are more likely to trust the accuracy of online video content about prostate cancer presented by Black physicians or patients compared with white presenters. @JAMANetworkOpen https://t.co/kX3g7ikp1E (@HemOncToday)
9 months ago
Clinical • Video
9ms
As a patient advocate, agree we need prospective trials. Would have hoped to see #QoL as an endpoint given the potential to delay/avoid systemic toxicities for oligomet #kidneycancer patients. Hugely important for patient decision making. (@DebMaskens)
9 months ago
Clinical
9ms
Great to sit down recently with the brilliant @apolo_andrea at ANZUP to discuss her perspective on biomarkers in bladder cancer, and promising future treatment strategies https://t.co/LHck0oQ3wj (@WeickhardtOnc)
9 months ago
9ms
Hot off the press...@AACR @CRC_AACR publication showing metronomic admin of chemo inhibits epithelial to mesenchymal transition in aggressive #prostatecancer Amazing collaboration b/w @UABHeersink @AuburnU @TuskegeeUniv @harvardmed @HopkinsMedicine https://t.co/j6VxpGW5EE (@RaisBahrami)
9 months ago
9ms
Clinical perspective on recurrence mechanisms of non-muscle Invasive #BladderCancer. Join @jteoh_hk @CUHKMedicine and @UroDocAsh @MDAndersonNews as they discuss 5 key mechanisms driving recurrence. Learn more about tackling this challenging cancer here > https://t.co/lBb3VccLTr (@urotoday)
9 months ago
Clinical
9ms
CyberKnife® radiation therapy treats prostate cancer with targeted radiation while sparing healthy tissue in only 5 sessions. Watch Dr. Sean Collins (@SbrtSean) takes us behind the scenes of a CyberKnife treatment. For more information, visit https://t.co/XTZOajUWHl. (@MedStarGUH)
9 months ago
Clinical
9ms
Calling all Urology HCPs - if you're interested in Bladder Cancer Surgery and education, please sign up for free below: 👉 Sign up here : https://t.co/2CK0moivgC 🗓️ 21st & 22nd September 📍 Western General Hospital, Edinburgh @ParamMariappan @KARLSTORZUK @PhotocureASA (@medacPharmaUK)
9 months ago
Clinical • Surgery
9ms
That’s a fantastic photo, Tony! This should be a poster for perseverance and for living life after a devastating metastatic prostate cancer diagnosis. You are an inspiration! (@TylerSbrt)
9 months ago
Metastases
9ms
Are there predictive #biomarkers of radiation therapy response in bladder cancer? 🎙️I chat w/ Prof. Ananya Choudoury @achoud72 @TheChristie on the latest research towards personalised care in bladder cancer radiation therapy #ANZUP23 @ANZUPtrials 👉 https://t.co/1ravkqLGDs (@lewisjwau)
9 months ago
9ms
🎥@BraunMDPhD of @YaleMed discusses the unique immune biology of kidney cancer and the need for targeted studies to understand resistance and improve anti-tumor immunity: ➡️https://t.co/xvWEtPBhOk #KCSM #ASCO23 #ImmunoOnc (@VJOncology)
9 months ago
9ms
Congratulations to the lab of @BraunMDPhD! The team has received approximately $5.75M in funding from @theNCI and @DeptofDefense to investigate the immune microenvironment of renal cell carcinoma. #RCC #kidneycancer #cancerresearch @YaleMed @SmilowCancer https://t.co/Y4ssOlviGt (@YaleCancer)
9 months ago
9ms
NEW KIDNEY MODEL WITH BLOOD PERFUSION 🩸 Please, take a look! @prokarurol @AntonioAlcarazA @vital_hevia @DrJM_Gaya @DrVitagliano😉 What do you think about it? #RAPN #kidneycancer #urology #surgery #partialnephrectomy https://t.co/HnzL6a3wL8 (@urotrainer)
9 months ago
Surgery
9ms
Predictive and prognostic role of the neutrophil-to-lymphocyte ratio in muscle invasive #BladderCancer treated with neoadjuvant chemotherapy and radical cystectomy. #BeyondTheAbstract with @mvdeimling, @VMS78880496, and @DrShariat > https://t.co/3WVW6evm8Q (@urotoday)
9 months ago
Clinical
9ms
Exciting news!! @FrancisMedical announces first patient treated in #VAPOR2 pivotal study for water vapor ablation of #ProstateCancer. #ReadNow for details of this study on UroToday > https://t.co/PjInMCXOAi @arvinkgeorge @tanejauro @roboticurology (@urotoday)
9 months ago
Clinical
9ms
Is there benefit to extended node dissection at time of radical cystectomy for metastatic #bladdercancer? How about excess toxicity? @koshkin85 of @UCSFCancer and Dr. Seth Lerner of @bcmhouston weigh in on SWOG S1011... https://t.co/cwAVU4Di1I (@GUOncologyNow)
9 months ago
Metastases
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login